AstraZeneca的Dato-DXd对转移性乳腺癌的试验显示,没有逐步的存活改善,但没有全面存活。 AstraZeneca's Dato-DXd trial in metastatic breast cancer showed progression-free survival improvement but not overall survival.

与化疗相比,AstraZeneca对转移性激素受体阳性,HER2低或阴性乳腺癌患者的达托帕马布德鲁克斯泰坎 (Dato- DXd) 的第三期试验没有显著改善整体生存率,尽管它达到其无进展生存率的主要终点. AstraZeneca's phase three trial for datopotamab deruxtecan (Dato-DXd) in metastatic hormone receptor-positive, HER2-low or negative breast cancer did not show significant overall survival improvement compared to chemotherapy, although it met its primary endpoint of progression-free survival. 该公司将与监管机构讨论调查结果。 The company will discuss the findings with regulators. 此外，阿斯利康的 Fasenra 获得了欧盟关于治疗嗜酸性肉芽肿性多血管炎的积极推荐。 Additionally, AstraZeneca's Fasenra received a positive EU recommendation for treating eosinophilic granulomatosis with polyangiitis.